Inhibrx Biosciences IncNASDAQ:INBX
- LAST PRICE13.8300
- TODAY'S CHANGE (%)-0.5000 (-3.4892%)
- Bid / Lots13.5400/ 1
- Ask / Lots15.4800/ 10
- Open / Previous Close14.3300 / 14.3300
- Day Range
- 52 Week Range
- Volume178,264
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INBX |
|---|---|---|
| 09:32 ET | 2733 | 14.33 |
| 09:35 ET | 2000 | 14.7677 |
| 09:37 ET | 5813 | 13.95 |
| 09:39 ET | 9428 | 13.95 |
| 09:42 ET | 130 | 13.6266 |
| 09:44 ET | 2000 | 13.63 |
| 09:46 ET | 2653 | 13.34 |
| 09:48 ET | 1201 | 13.36 |
| 09:51 ET | 200 | 13.32 |
| 09:55 ET | 100 | 13.5 |
| 09:57 ET | 749 | 13.5701 |
| 10:00 ET | 134 | 13.77 |
| 10:06 ET | 550 | 13.19 |
| 10:11 ET | 200 | 13.23 |
| 10:15 ET | 200 | 13.15 |
| 10:18 ET | 253 | 13.12 |
| 10:22 ET | 300 | 13.1 |
| 10:24 ET | 680 | 13.09 |
| 10:29 ET | 466 | 13 |
| 10:33 ET | 730 | 12.56 |
| 10:38 ET | 3103 | 13.22 |
| 10:40 ET | 925 | 13.29 |
| 10:42 ET | 1174 | 13.61 |
| 10:45 ET | 700 | 13.77 |
| 10:49 ET | 300 | 13.6601 |
| 10:51 ET | 624 | 13.77 |
| 10:56 ET | 100 | 13.735 |
| 10:58 ET | 400 | 13.98 |
| 11:00 ET | 900 | 14.08 |
| 11:02 ET | 3389 | 14 |
| 11:03 ET | 700 | 14.02 |
| 11:05 ET | 300 | 14 |
| 11:09 ET | 13492 | 14.02 |
| 11:12 ET | 6288 | 14.26 |
| 11:14 ET | 600 | 14.405 |
| 11:16 ET | 5224 | 14.56 |
| 11:18 ET | 20144 | 14.16 |
| 11:20 ET | 400 | 14.13 |
| 11:21 ET | 2200 | 14.1999 |
| 11:23 ET | 1300 | 14.3 |
| 11:25 ET | 1414 | 14.5 |
| 11:27 ET | 3700 | 14.495 |
| 11:30 ET | 11000 | 14.5799 |
| 11:32 ET | 500 | 14.41 |
| 11:36 ET | 100 | 14.32 |
| 11:38 ET | 4786 | 14.228 |
| 11:39 ET | 1300 | 14.305 |
| 11:41 ET | 300 | 14.215 |
| 11:43 ET | 200 | 14.15 |
| 11:45 ET | 1110 | 14.4 |
| 11:50 ET | 117 | 14.6 |
| 11:52 ET | 231 | 14.61 |
| 11:54 ET | 1343 | 14.5 |
| 11:57 ET | 500 | 14.485 |
| 12:48 ET | 1200 | 14.2116 |
| 12:50 ET | 1000 | 14.02 |
| 12:51 ET | 100 | 14.025 |
| 01:11 ET | 2000 | 13.94 |
| 01:26 ET | 200 | 13.9875 |
| 01:40 ET | 100 | 14.05 |
| 02:16 ET | 100 | 13.7901 |
| 02:21 ET | 1562 | 13.8 |
| 02:36 ET | 604 | 13.845 |
| 03:21 ET | 260 | 13.86 |
| 03:24 ET | 1290 | 13.86 |
| 03:26 ET | 1601 | 13.85 |
| 03:30 ET | 100 | 13.79 |
| 03:33 ET | 1100 | 13.79 |
| 03:35 ET | 100 | 13.81 |
| 03:37 ET | 450 | 13.81 |
| 03:39 ET | 400 | 13.78 |
| 03:44 ET | 288 | 13.7301 |
| 03:46 ET | 100 | 13.78 |
| 03:50 ET | 205 | 13.77 |
| 03:51 ET | 498 | 13.73 |
| 03:53 ET | 302 | 13.76 |
| 03:55 ET | 2705 | 13.75 |
| 03:57 ET | 1289 | 13.76 |
| 04:00 ET | 6003 | 13.83 |
Yesterday
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results, from 4:24PM ET on Thursday Nov 14, 2024 by Dow Jones
4:24PM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Inhibrx Biosciences 3Q Loss/Shr $2.84 >INBX, from 4:24PM ET on Thursday Nov 14, 2024 by Dow Jones
4:24PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 4, 2024
*DJ Inhibrx: Prevails in Trade Secret Case, from 5:11PM ET on Monday Nov 04, 2024 by Dow Jones
5:11PM ET on Monday Nov 04, 2024 by Dow JonesInhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation, from 4:00PM ET on Monday Nov 04, 2024 by Dow Jones
4:00PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibrx Biosciences Inc | 207.4M | 0.1x | --- |
Fulcrum Therapeutics Inc | 207.2M | -9.7x | --- |
Kyverna Therapeutics Inc | 207.1M | 0.0x | --- |
Benitec Biopharma Inc | 206.1M | -1.4x | --- |
TuHURA Biosciences Inc | 205.9M | -0.1x | --- |
Immutep Ltd | 320.7M | -9.0x | --- |
Company Information
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Contact Information
- Headquarters
- 11025 N. Torrey Pines Road, Suite 140LA JOLLA, CA, United States 92037
- Phone
- 858-795-4220
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.4M |
|---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $121.21 |
Book Value | $0.92 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 111.9 |
Price/Cash Flow (TTM) | 0.1x |
Operating Margin | 89,188.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
